Manuscripts
Showing 1530 manuscripts.
Live respiratory syncytial virus attenuated by M2-2 deletion and stabilized temperature sensitivity mutation 1030s is a promising vaccine candidate in children
Citation
E McFarland, R Karron, P Muresan, C Cunningham, J Libous, C Perlowski, B Thumar, D Gnanashanmugam, J Moye, E Schappell, E Barr, V Rexroad, L Fearn, S Spector, M Aziz, M Cielo, C Beneri, A Wiznia, C Luongo, P Collins, U Buchholz, IMPAACT 2011 Study Team. Live respiratory syncytial virus attenuated by M2-2 deletion and stabilized temperature sensitivity mutation 1030s is a promising vaccine candidate in children. Journal of Infectious Diseases. 2020. 221: 534-543. PMID: 31758177
Year
Journal
Study
Antenatal Intracellular Concentrations of Tenofovir Diphosphate and Emtricitabine Triphosphate and Associations Between Tenofovir Diphosphate and Severe Adverse Pregnancy Outcomes: IMPAACT-PROMISE (1077BF) Trial
Citation
Jim Aizire, Kristina Brooks, Mark Mirochnick, Patricia M Flynn, Kevin Butler, Jennifer J Kiser, George K Siberry, Terry Fenton, Mae Cababasay, Mary G Fowler, PROMISE Study Team. Antenatal Intracellular Concentrations of Tenofovir Diphosphate and Emtricitabine Triphosphate and Associations Between Tenofovir Diphosphate and Severe Adverse Pregnancy Outcomes: IMPAACT-PROMISE (1077BF) Trial. Journal of Acquired Immune Deficiency Syndromes. 2020. 83: 173-180. PMID: 31929405
Year
Journal
Study
Pregnancy outcomes of women conceiving on antiretroviral therapy (ART) compared to those commenced on ART during pregnancy
Citation
Gerhard Theron, Sean Brummel, Lee Fairlie, Mauricio Pinilla, Katie McCarthy, Maxensia Owor, Lameck Chinula, Bonus Makanani, Avy Violari, Dhayendre Moodley, Nahida Chakhtoura, Renee Browning, Risa Hoffman, MG Fowler. Pregnancy outcomes of women conceiving on antiretroviral therapy (ART) compared to those commenced on ART during pregnancy. Clinical Infectious Diseases. 2021. 73: e312-e320. PMID: 32564058
Year
Journal
Study
Time to treatment disruption in children with HIV-1 randomized to initial antiretroviral therapy with protease inhibitors versus non-nucleoside reverse transcriptase inhibitors
Citation
D Yin, C Ludema, S Cole, C Golin, W Miller, M Warshaw, R McKinney ; on behalf of the PENPACT-1 (PENTA 9 / PACTG 390) Study Team. Time to treatment disruption in children with HIV-1 randomized to initial antiretroviral therapy with protease inhibitors versus non-nucleoside reverse transcriptase inhibitors. PLoS One. 2020. 15: e0242405. PMID: 33226999
Year
Journal
Fosamprenavir with Ritonavir Pharmacokinetics during Pregnancy
Citation
Ahizechukwu C Eke, Jiajia Wang , Khadija Amin, David E Shapiro , Alice Stek , Elizabeth Smith, Nahida Chakhtoura, Michael Basar, Kathleen George, Katherine M Knapp, Esaú C João, Kittipong Rungruengthanakit , Edmund Capparelli, Sandra Burchett , Mark Mirochnick , Brookie M Best, P1026s Protocol Team. Fosamprenavir with Ritonavir Pharmacokinetics during Pregnancy. Antimicrobial Agents and Chemotherapy. 2020. 64: e02260-19. PMID: 32015036
Year
Journal
Study
Live-attenuated respiratory syncytial virus vaccine with M2-2 deletion and with SH non-coding region is highly immunogenic in children
Citation
Elizabeth J. McFarland, Ruth A. Karron, Petronella Muresan, Coleen K. Cunningham, Charlotte Perlowski, Jennifer Libous, Jennifer Oliva, Patrick Jean-Philippe, Jack Moye Jr, Elizabeth Schappell, Emily Barr, Vivian Rexroad, Laura Fearn, Mikhaela Cielo, Andrew Wiznia, Jaime G. Deville, Lijuan Yang, Cindy Luongo, Peter L.Collins, Ursula J. Buchholz. Live-attenuated respiratory syncytial virus vaccine with M2-2 deletion and with SH non-coding region is highly immunogenic in children. Journal of Infectious Diseases. 2020. 221: 2050-2059. PMID: 32006006
Year
Journal
Study
Alendronate Improves Bone Mineral Density in Children and Adolescents Perinatally Infected With Human Immunodeficiency Virus With Low Bone Mineral Density for Age
Citation
Denise L Jacobson, Jane C Lindsey, Catherine Gordon, Rohan Hazra, Hans Spiegel, Flavia Ferreira, Fabiana R Amaral, Jesica Pagano-Therrien, Aditya Gaur, Kathy George, jane Benson, George K Siberry. Alendronate Improves Bone Mineral Density in Children and Adolescents Perinatally Infected With Human Immunodeficiency Virus With Low Bone Mineral Density for Age. Clinical Infectious Diseases. 2020. 71: 1281-1288. PMID: 31573608
Year
Journal
Study
Decreased growth among antiretroviral drug and HIV-exposed uninfected versus unexposed children in Malawi and Uganda
Citation
Jim Aizire, Alla Sikorskii, Lillian Wambuzi Ogwang, Rachel Kawalazira, Alex Mutebe, Itziar Familiar-Lopez, MacPherson Mallewa, Taha Taha, Michael J Boivin, Mary Glenn Fowler, PROMISE NEURODEV Study Team. Decreased growth among antiretroviral drug and HIV-exposed uninfected versus unexposed children in Malawi and Uganda. AIDS. 2020. 34: 215-225. PMID: 31634154
Year
Journal
Study
Extended Prophylaxis With Nevirapine Does Not Affect Growth in HIV-Exposed Infants.
Citation
C Onyango-Makumbi, AH Owora, RS Mwiru, A Mwatha, AM Young, D Moodley, HM Coovadia, L Staranix-Chibanda, K Manji, Y Maldonado, P Richardson, P Andrew, K George, W Fawzi, MG Fowler. Extended Prophylaxis With Nevirapine Does Not Affect Growth in HIV-Exposed Infants.. Journal of Acquired Immune Deficiency Syndromes. 2019. 82: 377-385. PMID: 31567725
Year
Journal
Use of Modeling and Simulations to Determine Raltegravir Dosing in Neonates: A Model for Safely and Efficiently Determining Appropriate Neonatal Dosing Regimens: IMPAACT P1110
Citation
Diana F Clarke, Mark Mirochnick, Edward P Acosta, Edmund Capparelli, Anne Chain, Hedy Teppler, Betsy Smith, Jos Lommerse, International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1110 Study Team. Use of Modeling and Simulations to Determine Raltegravir Dosing in Neonates: A Model for Safely and Efficiently Determining Appropriate Neonatal Dosing Regimens: IMPAACT P1110. Journal of Acquired Immune Deficiency Syndromes. 2019. 82: 392-398. PMID: 31658182